Why the study?
Does extended treatment with rivaroxaban compared to aspirin or placebo reduce VTE recurrence at 1 year across different baseline risk factor profiles in patients with VTE?
Population
4,553 patients with venous thromboembolism categorized by baseline risk factors pooled from 2 randomized…
Comparison
Rivaroxaban 20 mg or 10 mg once daily for… vs Aspirin 100 mg or placebo
Design
Meta-analysis
Follow-up
1 year
Authors
Loading...
Risk profiles may guide extended VTE anticoagulation decisions; leaves open optimal thresholds for practice.
Does extended treatment with rivaroxaban compared to aspirin or placebo reduce VTE recurrence at 1 year across different baseline risk factor profiles in patients with VTE?
Patients with VTE provoked by minor persistent or transient risk factors have similar recurrence risks to those with unprovoked VTE, suggesting they may also benefit from extended anticoagulation.
Prins et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: